Abstract: Poster Presentations |

Inhaled Corticosteroid Treatment for Pregnant Women With Asthma: US Allergists and Pulmonologists Compared With Obstetricians and Gynecologists FREE TO VIEW

Nancy K. Ostrom, MD; Pamela Park, BA; Liza O’Dowd, MD
Author and Funding Information

Allergy and Asthma Medical Group and Research Center, San Diego, CA


Chest. 2003;124(4_MeetingAbstracts):138S-c-139S. doi:10.1378/chest.124.4_MeetingAbstracts.138S-c
Text Size: A A A
Published online


PURPOSE:  In December 2001, the US FDA upgraded the pregnancy category rating for budesonide dry-powder inhaler (BUD DPI) to Category B, making it the first ICS with this rating. Two surveys assessed the potential impact of this change on future treatment decisions by allergists and pulmonologists (A/Ps) and obstetricians and gynecologists (Ob/Gyns). (Budesonide inhalation suspension—indicated for use in children 12 months to 8 years of age—was upgraded to Pregnancy Category B in January 2003, making it the second ICS product with this rating.)

METHODS:  Participating physicians who had been practicing for 2-25 years were selected from a marketing database. The first survey included 15 allergists and 60 pulmonologists who spent ≥65% and ≥30% of their practice time, respectively, in an office/outpatient clinic. The second survey included 154 Ob/Gyns who were treating ≥5 asthma patients of childbearing age (15-44 years) per month.

RESULTS:  Both A/Ps and Ob/Gyns frequently prescribed ICS for their pregnant patients requiring asthma therapy (68% and 60%, respectively). More A/Ps were aware of a Category B ICS treatment choice (56% of A/Ps versus 30% of Ob/Gyns were aware that an ICS had been upgraded to Category B; 55% of the A/Ps knew that this ICS was BUD DPI, versus 16% of Ob/Gyns.) When informed of this upgrade, A/Ps reported that they would likely prescribe BUD DPI for 61% of their next 20 pregnant patients with asthma appropriate for ICS therapy versus 32% of their previous 20. Ob/Gyns reported that they would likely prescribe BUD DPI for 64% of their next 10 such patients compared with 6% of their previous 10.CONCLUSIONS: Treatment of pregnant women with asthma by A/Ps and Ob/Gyns is consistent with current national asthma treatment guidelines that recommend ICS as a first-line therapy for persistent asthma.

CLINICAL IMPLICATIONS:  Increased awareness of the availability of a Category B ICS (BUD DPI) will allow appropriate, informed consideration of treatment options for specialists treating pregnant patients with persistent asthma.

DISCLOSURE:  N.K. Ostrom, AstraZeneca LP, Grant monies. Professional consultation

Wednesday, October 29, 2003

12:30 PM - 2:00 PM




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
Novel targets of omalizumab in asthma. Curr Opin Pulm Med 2017;23(1):56-61.
Japanese guidelines for adult asthma 2017. Allergol Int 2017;66(2):163-189.
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543